JP2015522015A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522015A5 JP2015522015A5 JP2015520165A JP2015520165A JP2015522015A5 JP 2015522015 A5 JP2015522015 A5 JP 2015522015A5 JP 2015520165 A JP2015520165 A JP 2015520165A JP 2015520165 A JP2015520165 A JP 2015520165A JP 2015522015 A5 JP2015522015 A5 JP 2015522015A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- dihydroxyvitamin
- methylene
- subject
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UHMPCVGLSKFXHR-NFZXMVPNSA-N (1r,3r)-5-[(2e)-2-[(3as,7ar)-1-[(2s)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CCC([C@]2(CCC1)C)[C@H](CCCC(C)(C)O)C)=C\C=C1C[C@@H](O)C(=C)[C@H](O)C1 UHMPCVGLSKFXHR-NFZXMVPNSA-N 0.000 claims description 14
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000001631 haemodialysis Methods 0.000 claims description 3
- 230000000322 hemodialysis Effects 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 229940109239 creatinine Drugs 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261666264P | 2012-06-29 | 2012-06-29 | |
| US61/666,264 | 2012-06-29 | ||
| PCT/US2013/031574 WO2014003849A1 (en) | 2012-06-29 | 2013-03-14 | USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015522015A JP2015522015A (ja) | 2015-08-03 |
| JP2015522015A5 true JP2015522015A5 (enExample) | 2016-04-07 |
Family
ID=47997980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520165A Pending JP2015522015A (ja) | 2012-06-29 | 2013-03-14 | 続発性副甲状腺機能亢進症を治療するための２−メチレン−１９−ノル−（２０Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9205096B2 (enExample) |
| EP (1) | EP2866811A1 (enExample) |
| JP (1) | JP2015522015A (enExample) |
| KR (1) | KR20150030673A (enExample) |
| CN (1) | CN104394871A (enExample) |
| AU (1) | AU2013281217B2 (enExample) |
| BR (1) | BR112014032847A2 (enExample) |
| CA (1) | CA2877680C (enExample) |
| CL (1) | CL2014003565A1 (enExample) |
| CO (1) | CO7240358A2 (enExample) |
| HK (1) | HK1206600A1 (enExample) |
| IL (1) | IL236184A0 (enExample) |
| MX (1) | MX2015000076A (enExample) |
| MY (1) | MY172886A (enExample) |
| NZ (1) | NZ703347A (enExample) |
| RU (1) | RU2666995C2 (enExample) |
| SG (1) | SG11201408731WA (enExample) |
| WO (1) | WO2014003849A1 (enExample) |
| ZA (1) | ZA201500119B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY172886A (en) * | 2012-06-29 | 2019-12-13 | Wisconsin Alumni Res Found | Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism |
| CA2923758C (en) | 2013-09-27 | 2022-08-30 | Codexis, Inc. | Structure based predictive modeling |
| CA2923755C (en) | 2013-09-27 | 2023-03-14 | Codexis, Inc. | Automated screening of enzyme variants |
| CN103533522A (zh) * | 2013-10-25 | 2014-01-22 | 从兴技术有限公司 | 短信稽核的方法及系统 |
| US10220047B2 (en) * | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US10369161B2 (en) * | 2014-12-30 | 2019-08-06 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism |
| US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| US10105375B2 (en) | 2016-08-30 | 2018-10-23 | Wisconsin Alumni Research Foundation | Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040043971A1 (en) | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
| US5843928A (en) | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US6306844B1 (en) | 1997-03-17 | 2001-10-23 | Wisconsin Alumni Research Foundation | Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength |
| US6136799A (en) | 1998-04-08 | 2000-10-24 | Abbott Laboratories | Cosolvent formulations |
| US6673782B2 (en) | 1999-04-29 | 2004-01-06 | Wisconsin Alumni Research Foundation | Treatment of systemic lupus erythematosis |
| CA2404335C (en) | 2000-03-27 | 2009-01-06 | Wisconsin Alumni Research Foundation | Vitamin d compounds used to stabilize kidney transplants |
| MXPA03000406A (es) * | 2000-07-14 | 2003-06-06 | Wisconsin Alumni Res Found | Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos. |
| US20080249068A1 (en) | 2002-09-05 | 2008-10-09 | Deluca Hector F | Method of Extending the Dose Range of Vitamin D Compounds |
| US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
| US20060171983A1 (en) | 2003-07-30 | 2006-08-03 | Jin Tian | Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease |
| JP2007505882A (ja) * | 2003-09-19 | 2007-03-15 | ファイザー・プロダクツ・インク | 脆弱、筋損傷又はサルコペニアの治療のための２−アルキリデン−１９−ノル−ビタミンｄ誘導体 |
| US7704980B2 (en) | 2003-10-08 | 2010-04-27 | Wisconsin Alumni Research Foundation | Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds |
| US7214671B2 (en) * | 2004-02-19 | 2007-05-08 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases |
| EP1853274B1 (en) | 2005-02-11 | 2013-01-23 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor- (20s-24s) - 1alpha, 25-dihydroxyvitamine-d2 |
| US7528122B2 (en) * | 2006-02-02 | 2009-05-05 | Wisconsin Alumni Research Foundation | Vitamin D analog—NEL, methods and uses thereof |
| CA2764577C (en) * | 2009-08-03 | 2017-12-19 | Wisconsin Alumni Research Foundation | Method of preventing renal disease and treating symptoms thereof |
| CA2794006C (en) | 2010-03-23 | 2017-11-28 | Wisconsin Alumni Research Foundation | (20s)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-dihydroxyvitamin d3 and (20r)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-hydroxyvitamin d3 |
| MY172886A (en) * | 2012-06-29 | 2019-12-13 | Wisconsin Alumni Res Found | Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism |
-
2013
- 2013-03-14 MY MYPI2014003594A patent/MY172886A/en unknown
- 2013-03-14 EP EP13712121.6A patent/EP2866811A1/en not_active Withdrawn
- 2013-03-14 SG SG11201408731WA patent/SG11201408731WA/en unknown
- 2013-03-14 KR KR20147036464A patent/KR20150030673A/ko not_active Ceased
- 2013-03-14 AU AU2013281217A patent/AU2013281217B2/en not_active Ceased
- 2013-03-14 CA CA2877680A patent/CA2877680C/en not_active Expired - Fee Related
- 2013-03-14 MX MX2015000076A patent/MX2015000076A/es unknown
- 2013-03-14 HK HK15107093.4A patent/HK1206600A1/xx unknown
- 2013-03-14 WO PCT/US2013/031574 patent/WO2014003849A1/en not_active Ceased
- 2013-03-14 JP JP2015520165A patent/JP2015522015A/ja active Pending
- 2013-03-14 NZ NZ703347A patent/NZ703347A/en not_active IP Right Cessation
- 2013-03-14 US US13/828,090 patent/US9205096B2/en not_active Expired - Fee Related
- 2013-03-14 RU RU2015102831A patent/RU2666995C2/ru not_active IP Right Cessation
- 2013-03-14 CN CN201380034681.7A patent/CN104394871A/zh active Pending
- 2013-03-14 BR BR112014032847A patent/BR112014032847A2/pt not_active Application Discontinuation
-
2014
- 2014-03-07 US US14/201,091 patent/US9034853B2/en not_active Expired - Fee Related
- 2014-12-11 IL IL236184A patent/IL236184A0/en unknown
- 2014-12-29 CL CL2014003565A patent/CL2014003565A1/es unknown
-
2015
- 2015-01-08 ZA ZA2015/00119A patent/ZA201500119B/en unknown
- 2015-01-23 CO CO15013584A patent/CO7240358A2/es unknown
- 2015-11-20 US US14/947,142 patent/US9717744B2/en not_active Expired - Fee Related
-
2017
- 2017-05-24 US US15/604,069 patent/US10046000B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522015A5 (enExample) | ||
| JP2022180461A5 (enExample) | ||
| ES2494015T3 (es) | Composiciones para tratar nauseas y vómitos de origen central | |
| RU2015102831A (ru) | ПРИМЕНЕНИЕ 2-МЕТИЛЕН-19-НОР-(20S)-1α, 25-ДИГИДРОКСИВИТАМИНА D3 ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОГО ГИПЕРПАРАТИРЕОЗА | |
| JP2012180381A5 (enExample) | ||
| JP2016518387A5 (enExample) | ||
| JP2014528474A5 (enExample) | ||
| SI2625199T1 (en) | Procedures for treating psoriasis using IL-17 antagonists | |
| JP2011173928A5 (enExample) | ||
| JP2010525050A5 (enExample) | ||
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP2012193216A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| JP2013521303A5 (enExample) | ||
| JP2018505882A5 (enExample) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2016510343A5 (enExample) | ||
| HRP20241360T1 (hr) | Optimirano doziranje diaminofenotiazina u populacijama | |
| JP2016534081A5 (ja) | ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 | |
| IL265761B2 (en) | Oral terlipressin compositions for use in treatment of ascites | |
| RU2015134421A (ru) | Применение левоцетиризина и монтелукаста при лечении травматических повреждений | |
| JP2016505050A5 (enExample) | ||
| JP2017514858A5 (enExample) | ||
| JP2013501049A5 (enExample) | ||
| JPWO2019241442A5 (enExample) |